Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Lockhart on Strategies for Targeting the RAS/RAF/MEK/ERK Pathway in CRC

January 14th 2020

A. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational strategies targeting the RAS/RAF/MEK/ERK pathway in colorectal cancer (CRC).

Role of Immunotherapy Agents Grows in Metastatic Colorectal Cancer

January 11th 2020

The standard of care in the second line for patients with mismatch repair–deficient metastatic colorectal cancer has shifted to favor therapy utilizing immunotherapeutic agents, according to Howard Hochster, MD.

Expert Highlights Immunotherapy Combo Strategies in Relapsed/Refractory CRC

January 10th 2020

A. Craig Lockhart, MD, MHS, discusses ongoing developments and the future of immunotherapy in colorectal cancer.

Dr Weinberg on Varying Treatment Options in Metastatic Colorectal Cancer

January 9th 2020

Benjamin Weinberg, MD, discusses varying treatment options for patients with metastatic colorectal cancer.

Dr. Vulfovich on Molecular Testing in Colorectal Cancer

January 7th 2020

Michel Vulfovich, MD, discusses molecular testing in colorectal cancer.

Dr. Lockhart on Next Steps for Regorafenib and TAS-102 in mCRC

January 4th 2020

A. Craig Lockhart, MD, MHS, professor, associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses next steps for regorafenib (Stivarga) and TAS-102 (trifluridine/tipiracil; Lonsurf) in metastatic colorectal cancer (mCRC).

Dr. Vulfovich on Broad Molecular Profiling in mCRC

December 20th 2019

Michel Vulfovich, MD, medical director, Sickle Cell Disease and Gynecology Oncology programs, Memorial Healthcare System, discusses the utility of broad molecular profiling in metastatic colorectal cancer (mCRC).

FDA Grants Priority Review to Encorafenib/Cetuximab Combo for BRAF+ mCRC

December 19th 2019

The FDA has granted a priority review designation to a supplemental new drug application for the combination of encorafenib and cetuximab as a treatment for patients with advanced BRAF V600E–mutant metastatic colorectal cancer following up to 2 prior lines of therapy.

Dr. Kim on Immunotherapy in CRC

December 18th 2019

Richard Kim, MD, discusses the use of immunotherapy in colorectal cancer.

Dr. Benson on Treatment for Patients With Resectable Colorectal Cancer

December 18th 2019

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses treatment for patients with resectable colorectal cancer (CRC).

Dr. Eng on Addressing Unmet Needs for Colorectal Cancer

December 17th 2019

Cathy Eng, MD, FACP, FASCO, discusses ways to address unmet needs for young adults with colorectal cancer.

Dr. Kim on Optimizing Outcomes With Molecular Profiling in mCRC

December 13th 2019

Richard Kim, MD, discusses how molecular profiling can be used to optimize outcomes in patients with metastatic colorectal cancer.

Dr. Corcoran on the Utility of Regorafenib in CRC

December 10th 2019

Ryan B. Corcoran, MD, PhD, discusses the utility of regorafenib in colorectal cancer.

Dr. Benson on MSI Testing in Colorectal Cancer

December 10th 2019

Al B. Benson, MD, discusses the implications of microsatellite instability testing on patients with colorectal cancer.

Next Steps for Wnt Research in Colorectal Cancer

December 6th 2019

Luke Dow, PhD, discusses the next steps for researching the Wnt pathway in colorectal cancer.

Dr. Corcoran on Promising Combination Strategies With Immunotherapy in mCRC

December 5th 2019

Ryan B. Corcoran, MD, PhD, discusses promising combination strategies with immunotherapy in metastatic colorectal cancer.

Dr. Benson on the Ongoing Research With Immunotherapy in mCRC

December 3rd 2019

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses ongoing research with immunotherapy in metastatic colorectal cancer (mCRC).

Genomic Era Trials Drive Discovery

December 2nd 2019

Innovative clinical trials designed to exploit the explosion of data on the drivers of cancer are demonstrating value as tools to explore potential signals of efficacy across tumor types, according to oncology experts. These studies have become a feature of the drug discovery landscape in oncology and are likely to remain part of the fabric of clinical research in the genomic era.

Dr. Patel on Sequencing Therapy in Rectal Cancer

November 28th 2019

Timil Patel, MD, discusses an optimal sequencing strategy in rectal cancer.

Novel Therapy May Boost Efficacy of Chemotherapy Backbone in mCRC

November 18th 2019

In a phase III trial, investigators are examining if arfolitixorin can supplant leucovorin calcium, a widely used component of combination regimens in patients with metastatic colorectal cancer.